DGIdb - CARBOPLATIN Drug Record

CARBOPLATIN chembl:CHEMBL1351 ApprovedAntineoplasticImmunotherapy

Alternate Names:

PARAPLATIN
NSC-241240
CARBOPLATIN
JM-8
NSC-201345
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
CBDCA
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
drugbank:00958
chembl:CHEMBL1351
rxcui:40048
chemidplus:41575-94-4
pubchem.compound:10339178

Drug Info:

(6 More Sources)

Publications:

Samimi et al., 2003, Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients., Clin. Cancer Res.
Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J
Samimi et al., 2004, Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B., Mol. Pharmacol.
He YJ et al., 2016, Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial., Pharmacogenomics J
Ishimoto et al., 2002, Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli., Pharmacogenetics
Sawers et al., 2014, Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines., Br. J. Cancer
McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
Fader AN et al., 2018, Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu., J Clin Oncol
Koivusalo et al., 2002, Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand., Cancer Res.
Westfall et al., 2005, Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment., Mol. Cancer Ther.
Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
Pertusini et al., 2001, Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy., Blood
Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
Leijen et al., 2016, Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months., J. Clin. Oncol.
Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
Vollebergh et al., 2011, An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients., Ann. Oncol.
Pérez-Ramírez C et al., 2019, Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients., Pharmacogenomics J
Pérez-Ramírez C et al., 2016, Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients., Pharmacol Res
Sullivan I et al., 2014, Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy., Cancer Lett
Yan L et al., 2012, Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy., Pharmacogenomics
Khrunin A et al., 2012, Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins., Pharmacogenomics
Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
Tzvetkov MV et al., 2011, Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms., Pharmacogenomics
Zucali PA et al., 2011, Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin., Clin Cancer Res
Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
Khrunin AV et al., 2010, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients., Pharmacogenomics J
Kalikaki A et al., 2009, DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer., Clin Lung Cancer
Tibaldi C et al., 2008, Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients., Clin Cancer Res
Ando et al., 1998, EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway., Jpn. J. Cancer Res.
Flamm et al., Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin., Anticancer Res.
Xu JL et al., 2012, Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population., Asian Pac J Cancer Prev
Wilson et al., 2016, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma., Clin. Cancer Res.
Eberhard et al., 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib., J. Clin. Oncol.
Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
Ratner et al., 2012, A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer., Oncogene
Tonsing-Carter et al., 2015, Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model., Mol. Cancer Ther.
Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
Richter et al., 2015, WIP1 phosphatase as a potential therapeutic target in neuroblastoma., PLoS ONE
Reles et al., 2001, Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer., Clin. Cancer Res.
Hyman et al., 2015, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors., Cancer Chemother. Pharmacol.
Bachmann HS et al., 2015, The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients., Br J Clin Pharmacol
Cui LH et al., 2011, Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC., Pharmacogenomics
Patiño-García A et al., 2009, Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression., J Pediatr
Oizumi S et al., 2012, Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial., Oncologist
Han et al., 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung., J. Clin. Oncol.
Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
Goto K et al., 2012, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer., J Thorac Oncol
Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
Maemondo et al., 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR., N. Engl. J. Med.
Mitsudomi et al., 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial., Lancet Oncol.
Mok et al., 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma., N. Engl. J. Med.
Zhang et al., 2004, [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro]., Zhonghua Fu Chan Ke Za Zhi
Oguri et al., Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients., Anticancer Res.
Hu L et al., 2016, Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients., J Clin Pharmacol
Yamasaki S et al., 2015, UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan., Ann Hematol
Xu X et al., 2012, Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients., Clin Exp Pharmacol Physiol
Ekhart C et al., 2008, Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin., Pharmacogenet Genomics
Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
Chen JS et al., 2010, A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma., Anticancer Drugs
Smit EF et al., 2009, Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer., J Clin Oncol
Gandara et al., 2009, Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics., J. Clin. Oncol.
Sato Y et al., 2011, Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel., J Thorac Oncol
Park HS et al., 2016, Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy., Pharmacogenet Genomics
Mbatchi LC et al., 2015, Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination., Pharmacogenomics
Xu X et al., 2013, The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients., Lung Cancer
Santibáñez M et al., 2013, The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer., Pharmacogenet Genomics
Sheffield et al., 2015, Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing., PLoS ONE
Kaklamani et al., 2015, Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)., Breast Cancer Res. Treat.

CARBOPLATIN MTR

Interaction Score: 1.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 21605004 19159907

Sources:
PharmGKB
CARBOPLATIN MAD1L1

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23407047

Sources:
PharmGKB
CARBOPLATIN EIF3A

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23127338

Sources:
PharmGKB
CARBOPLATIN DSCAM

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21079520

Sources:
PharmGKB
CARBOPLATIN SLC31A1

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22725681

Sources:
PharmGKB
CARBOPLATIN C6ORF15

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN MUCL3

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN DOCK8

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN MSH5

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN ETS2

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN ATAT1

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN PPP1R18

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN CDSN

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN XYLT2

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN ATP7B

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15213293 26194361

Sources:
NCI PharmGKB
CARBOPLATIN ERCC1

Interaction Score: 0.6

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB
CARBOPLATIN PRRC2A

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN HCP5

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN GPX5

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CARBOPLATIN RNF8

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
CARBOPLATIN TRIM5

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CARBOPLATIN GCLC

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11911273

Sources:
NCI
CARBOPLATIN SERPINA5

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN FNTB

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26033044

Sources:
PharmGKB
CARBOPLATIN SOX10

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
PharmGKB
CARBOPLATIN PSORS1C1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN NF2

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25798586

Sources:
CIViC
CARBOPLATIN BARD1

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
CARBOPLATIN TP73

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12499281

Sources:
NCI
CARBOPLATIN ACSS2

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CARBOPLATIN ATP7A

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14676106

Sources:
NCI
CARBOPLATIN MTHFR

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29662106 27995989 21605004 20634689 19307503 19159907

Sources:
PharmGKB
CARBOPLATIN MAP3K1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CARBOPLATIN ERCC2

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19470925

Sources:
CIViC
CARBOPLATIN XRCC1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16875718

Sources:
CIViC
CARBOPLATIN SLC19A1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16875718

Sources:
PharmGKB
CARBOPLATIN HLA-C

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN SMAD4

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
CARBOPLATIN SLCO1B3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26641474 26267044

Sources:
PharmGKB
CARBOPLATIN GSR

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26194361

Sources:
PharmGKB
CARBOPLATIN BRCA2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib + Carboplatin

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
25847936

Sources:
JAX-CKB CIViC
CARBOPLATIN CDKN1A

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12168940

Sources:
NCI
CARBOPLATIN RAF1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CARBOPLATIN GSTT1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CARBOPLATIN CDKN2A

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
CARBOPLATIN SERPINC1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN NRG1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23390248

Sources:
CIViC
CARBOPLATIN GSTP1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12360105 25010864

Sources:
NCI CIViC
CARBOPLATIN BRCA1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Carboplatin + VX-970

Indication/Tumor Type ovarian cancer

Response Type sensitive

PMIDs:
25847936 27998224 25824335 21135055

Sources:
ClearityFoundationBiomarkers JAX-CKB CIViC
CARBOPLATIN BCL2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
ClearityFoundationBiomarkers PharmGKB
CARBOPLATIN ERBB3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
CARBOPLATIN EGFR

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22581822 22370314 22285168 21900837 21783417 20573926 20022809 19692680 22139083

Sources:
CIViC PharmGKB
CARBOPLATIN KRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy XL147 + Carboplatin

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
26307133 21216929 16043828 27998224 25637314 22139083

Sources:
JAX-CKB CIViC
CARBOPLATIN BIRC5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15347474

Sources:
NCI
CARBOPLATIN UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25055799

Sources:
PharmGKB
CARBOPLATIN VEGFA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26194361

Sources:
PharmGKB
CARBOPLATIN MCL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10081494

Sources:
NCI
CARBOPLATIN NRAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
CARBOPLATIN PIK3CA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy XL147 + Carboplatin + Paclitaxel

Indication/Tumor Type colorectal cancer

Response Type resistant

PMIDs:
16275998 21216929

Sources:
JAX-CKB NCI PharmGKB
CARBOPLATIN CDK2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26006067

Sources:
CIViC
CARBOPLATIN PDGFRA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
CARBOPLATIN PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25672916

Sources:
CIViC PharmGKB
CARBOPLATIN TNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31616045

Sources:
PharmGKB
CARBOPLATIN AKT1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22901187

Sources:
PharmGKB
CARBOPLATIN ERBB2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039 29584549

Sources:
CIViC PharmGKB
CARBOPLATIN SCN10A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26194361

Sources:
PharmGKB
CARBOPLATIN CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26179145

Sources:
PharmGKB
CARBOPLATIN OPRM1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
PharmGKB
CARBOPLATIN MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Imatinib + Carboplatin + Paclitaxel

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB
CARBOPLATIN TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy MK-1775 + Carboplatin

Indication/Tumor Type ovarian cancer

Response Type predicted – resistant

PMIDs:
26494859 25567130 25658463 27998224 11595686

Sources:
JAX-CKB CIViC
CARBOPLATIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11157479

Sources:
NCI
CARBOPLATIN KAT2A

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBOPLATIN APEX1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBOPLATIN ALDH1A1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18854779

Sources:
PharmGKB
CARBOPLATIN USP1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBOPLATIN POLK

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBOPLATIN HSD17B10

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBOPLATIN MAPT

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBOPLATIN VDR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

NCI: CBDCA
- Version: 14-September-2017
Alternate Names:

C1282 NCI drug code

Drug Info:

Publications:

Oguri et al., Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients., Anticancer Res.

NCI: CARBOPLATIN

Version: 14-September-2017

Alternate Names:

C1282 NCI drug code

Drug Info:

Publications:

Pertusini et al., 2001, Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy., Blood

Samimi et al., 2003, Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients., Clin. Cancer Res.

Zhang et al., 2004, [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro]., Zhonghua Fu Chan Ke Za Zhi

JAX-CKB: Carboplatin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)

Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.

Vollebergh et al., 2011, An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients., Ann. Oncol.

PharmGKB: carboplatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One

Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J

McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res

CIViC: CARBOPLATIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.

Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.

Hyman et al., 2015, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors., Cancer Chemother. Pharmacol.

DTC: CARBOPLATIN
- Version: 02-September-2020
Alternate Names:

CHEMBL1351 ChEMBL Drug ID

Drug Info:

Publications:
DTC: PARAPLATIN
- Version: 02-September-2020
Alternate Names:

CHEMBL288376 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Carboplatin
- Version: 2020.06.01
Alternate Names:

D0X7HM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1351
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: CARBOPLATIN
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:

combination therapy	Imatinib + Carboplatin + Paclitaxel
Indication/Tumor Type	melanoma
Response Type	sensitive

combination therapy	Veliparib + Carboplatin
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

combination therapy	Carboplatin + VX-970
Indication/Tumor Type	ovarian cancer
Response Type	sensitive

combination therapy	XL147 + Carboplatin
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

combination therapy	XL147 + Carboplatin + Paclitaxel
Indication/Tumor Type	colorectal cancer
Response Type	resistant

Evidence Type	Actionable
Approval Status	Clinical Study
Response Type	sensitive

combination therapy	MK-1775 + Carboplatin
Indication/Tumor Type	ovarian cancer
Response Type	predicted – resistant

CARBOPLATIN Drug Record

CARBOPLATIN chembl:CHEMBL1351 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 21605004 19159907

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23407047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23127338

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21079520

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22725681

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15213293 26194361

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31616045

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21636554

Interaction Types & Directionality:

n/a

PMIDs:
29662106 21605004 19159907

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23407047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23127338

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21079520

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22725681

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15213293 26194361

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29662106 27498158 25069034 22329723 22188361 22026922 21902499 21262916 21057378 19786980 19362955 18347182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21636554

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30071039

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11911273

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26033044

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23963862

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31616045

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25798586